ASBP · Aspire Biopharma Holdings, Inc.
$7.76
+0.22 (+2.92%)
At close · Jul 22
Market Cap
$10.05M
Shares
1.30M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$7.76
Open$7.47
Day$6.96–8.17
52W$0.11–35.00
Avg vol 30d531K
Short int101K · 7.8% float · 1.0d
Short vol34%
DataApr 2022–Jul 2026
Filing10-Q · May 15
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 15, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 16.6 · calm
Equity put/call 0.67
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+67%
above
Price vs 50-day avg
+30%
above
RSI (14)
70
neutral
MACD trend
Positive
52-week position
22%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+26%
trailing
6-month return
+388%
trailing
YTD return
+47%
this year
Relative strength
+381%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $6 › 200d $5 — 50d above 200d
Institutional flow
Accumulating
+13 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
7.83% of float · ▼ -70.0% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
13 holders — 13F breadth
Squeeze score
57
elevated · 0–100
Fundamentals
Gross margin
-2%
EPS growth
−762%
Y/Y
Balance sheet
$1.0M
net cash
Quant / Vol
risk profile
Volatility
2898%
annualized · 1-yr
Max drawdown
−99%
past year
ATR
9.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+67%
Bullish
Price vs 50-day avg
+30%
Bullish
RSI (14)
70
Neutral
MACD trend
Positive
Bullish
52-week position
22%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $6 › 200d $5 — 50d above 200d
Institutional flow
Accumulating
+13 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
7.83% of float · ▼ -70.0% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
13 holders — 13F breadth
Price context
position in its 52-week range
52-wk low $0
Now $8 · 22%
52-wk high $35
vs 200-day avg +67%
vs 50-day avg +30%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ASBP
this stock
Aspire Biopharma Holdings, Inc.
|
$10.05M | +47.0% | — | — | 7.8% |
|
ONC
BeOne Medicines Ltd.
|
$462.38B | +5.3% | +22179.2% | 941.0 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$119.94B | +4.2% | +46.2% | 28.1 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$68.27B | -15.5% | +20.8% | 15.9 | 3.3% |
|
ARGX
Argenx SE
|
$53.28B | +1.3% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ASBP | +28.5% | +25.8% | +388.1% | +45.3% | +47.0% |
| SPY | -1.0% | +1.9% | +7.5% | +0.1% | +9.6% |
| vs SPY | +29.5% | +23.9% | +380.6% | +45.2% | +37.4% |